Sphingosine 1Phosphate Receptor 1 Endothelial Differentiation G Protein...
Sphingosine 1Phosphate Receptor 1 Endothelial Differentiation G Protein Coupled Receptor 1 or Sphingosine 1 Phosphate Receptor Edg 1 or CD363 or S1PR1 Pipeline Review H2 2017SummarySphingosine...
View ArticleImmune Pharmaceuticals Provides R&D and Business Update and Summary of Recent...
Immune Pharmaceuticals Inc. NASDAQIMNP Immune or the Company provided the following R&D and business update and summary of recent financial highlights. R&D Update Immune continues to...
View ArticleFDA approves Humira biosimilar Cyltezo
The FDA has approved the second biosimilar to Humira Cyltezo for several gastroenterological rheumatological and dermatological indications.Cyltezo adalimumabadbm Boehringer Ingelheim a biosimilar to...
View ArticleAutoimmune diseases increase cardiovascular and mortality risk
IMIM Hospital del Mar Medical Research Institute Researchers from the Hospital del Mar Medical Research Institute IMIM and IDIAP Jordi Gol have just published an article showing that autoimmune...
View ArticleUS Gastroenterologists May Thwart Uptake of New Biosimilars Such as Pfizer's...
EXTON Pa. Aug. 29 2017 PRNewswire According to the Q3 update of RealTime Dynamix Inflammatory Bowel Disease IBD US gastroenterologists n103 report a significant decline in the percent of their UC...
View ArticleArena Pharmaceuticals to Participate in Upcoming Investor Conferences
SAN DIEGO Aug. 29 2017 PRNewswire Arena Pharmaceuticals Inc. NASDAQ ARNA today announced that members of its senior management team will participate in the following investor conferences in September...
View ArticleBoehringer Ingelheim Pharmaceuticals Inc. receives FDA approval for Cyltezo...
RIDGEFIELD Conn. Aug. 29 2017 PRNewswire Boehringer Ingelheim Pharmaceuticals Inc. today announced that the U.S. Food and Drug Administration FDA approved Cyltezo a biosimilar to HumiraĆ in a prefilled...
View ArticleImmune Pharmaceuticals Receives NASDAQ Letter
Immune Pharmaceuticals Inc. NASDAQ IMNP "Immune" announced today that on August 23 2017 the Company received written notice from the Listing Qualifications Department of The NASDAQ Stock Market LLC...
View ArticleTaiwanJ Pharmaceuticals Co Ltd 6549 Pharmaceuticals Healthcare Deals and...
SummaryTaiwanJ Pharmaceuticals Co Ltd TaiwanJ is a pharmaceutical company that develops and commercialize firstinclass small molecules as TLR4 antagonists. The company's TLR4 is a transmembrane protein...
View ArticleTillotts Pharma AG Pharmaceuticals Healthcare Deals and Alliances Profile...
SummaryTillotts Pharma AG Tillotts a subsidiary of Zeria Pharmaceutical Co Ltd is a healthcare solution provider that develops licenses and markets pharmaceutical products medical devices and...
View ArticleUpdate on Enteral Nutrition and Pediatric Crohn Disease
Metaanalysis results confirm enteral nutrition as an effective option in treating Crohn disease in children.
View ArticleCrohn's Disease Regional Enteritis Pipeline Review H2 2017 Report Updated...
Crohn's Disease Regional Enteritis Pipeline Review H2 2017SummaryGlobal Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Crohn's Disease Regional Enteritis Pipeline Review...
View ArticleT Cell Surface Glycoprotein CD3 Epsilon Chain T Cell Surface Antigen T3Leu 4...
T Cell Surface Glycoprotein CD3 Epsilon Chain T Cell Surface Antigen T3Leu 4 Epsilon Chain or CD3E Pipeline Review H2 2017SummaryAccording to the recently published report 'T Cell Surface Glycoprotein...
View ArticleTxCell SA TXCL Pharmaceuticals Healthcare Deals and Alliances Profile Report...
SummaryTxcell SA Txcell is a biotechnology company that develops and innovates cellbased immunotherapy utilizing antigen specific regulatory Tcells. The company's pipeline products include cartreg...
View ArticleTiGenix NV TIG Pharmaceuticals Healthcare Deals and Alliances Profile Report...
SummaryTiGenix NV TiGenix is a biopharmaceutical company that develops and commercializes novel therapeutics. Its product portfolio includes AlloCSC01 AlloCSC02 Cx611 and Cx601. The company develops...
View ArticleInDex Pharmaceuticals AB INDEX Financial and Strategic SWOT Analysis Review...
SummaryInDex Pharmaceuticals AB InDex Pharmaceuticals is a biopharmaceutical company that provides immunological disease treatments. The company offers Kappaproct which is in Phase III clinical trials...
View ArticleSoligenix to Present at the 8th Annual Investing for Cures Forum in New York...
PRINCETON N.J. Sept. 5 2017 PRNewswire Soligenix Inc. Nasdaq SNGX Soligenix or the Company a latestage biopharmaceutical company focused on developing and commercializing products to treat rare...
View ArticleU.S. Medical Cannabis Market Size Worth USD 19.48 Billion By 2024 Hexa Research
FELTON California September 6 2017 PRNewswire The U.S. medical cannabis market is expected to be valued at USD 19.48 billion by 2024 driven by its numerous medical benefits particularly by patients...
View ArticleArena Pharmaceuticals to Present Additional PreClinical Data on Ralinepag for...
SAN DIEGO Sept. 6 2017 PRNewswire Arena Pharmaceuticals Inc. NASDAQ ARNA will present additional detailed preclinical pharmacology and pharmacokinetic data on ralinepag APD811 the Company's...
View ArticleRebiotix Appoints Edward S. Burd Ph.D. to Head of Regulatory Affairs
ROSEVILLE Minn. Sept. 6 2017 PRNewswire Rebiotix Inc. a latestage clinical microbiome company focused on harnessing the power of the human microbiome to treat challenging diseases today announced the...
View Article